#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-14	Load-Dependent	_
1-2	15-32	Hyperdeactivation	_
1-3	33-35	of	_
1-4	36-39	the	_
1-5	40-47	Default	_
1-6	48-52	Mode	_
1-7	53-60	Network	_
1-8	61-63	in	_
1-9	64-70	People	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-10	71-75	With	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-11	76-89	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-12	90-103	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-13	104-106	is	_
1-14	107-117	associated	_
1-15	118-122	with	_
1-16	123-133	impairment	_
1-17	134-136	in	_
1-18	137-138	a	_
1-19	139-144	range	_
1-20	145-147	of	_
1-21	148-157	cognitive	_
1-22	158-167	functions	_
1-23	168-169	.	_

2-1	170-182	Neuroimaging	_
2-2	183-190	studies	_
2-3	191-195	have	_
2-4	196-204	reported	_
2-5	205-210	lower	_
2-6	211-212	,	_
2-7	213-216	but	_
2-8	217-221	also	_
2-9	222-228	higher	_
2-10	229-230	,	_
2-11	231-243	task-induced	_
2-12	244-254	activation	_
2-13	255-267	accompanying	_
2-14	268-276	impaired	_
2-15	277-288	performance	_
2-16	289-290	.	_

3-1	291-302	Differences	_
3-2	303-305	in	_
3-3	306-315	task-load	_
3-4	316-319	and	_
3-5	320-323	the	_
3-6	324-331	ability	_
3-7	332-334	of	_
3-8	335-341	people	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-9	342-346	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-10	347-360	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-11	361-362	(	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-12	363-366	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-13	367-368	)	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-14	369-371	to	_
3-15	372-376	stay	_
3-16	377-384	engaged	_
3-17	385-387	in	_
3-18	388-391	the	_
3-19	392-401	cognitive	_
3-20	402-412	operations	_
3-21	413-419	probed	_
3-22	420-426	appear	_
3-23	427-429	to	_
3-24	430-438	underlie	_
3-25	439-443	such	_
3-26	444-457	discrepancies	_
3-27	458-459	.	_

4-1	460-469	Similarly	_
4-2	470-471	,	_
4-3	472-484	task-induced	_
4-4	485-497	deactivation	_
4-5	498-500	of	_
4-6	501-504	the	_
4-7	505-512	default	_
4-8	513-517	mode	_
4-9	518-525	network	_
4-10	526-527	(	_
4-11	528-531	DMN	_
4-12	532-533	)	_
4-13	534-537	was	_
4-14	538-544	weaker	_
4-15	545-547	in	_
4-16	548-551	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
4-17	552-560	relative	_
4-18	561-563	to	_
4-19	564-571	healthy	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-20	572-579	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-21	580-588	subjects	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-22	589-590	(	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-23	591-594	HCS	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-24	595-596	)	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
4-25	597-599	in	_
4-26	600-604	most	_
4-27	605-612	studies	_
4-28	613-614	,	_
4-29	615-618	but	_
4-30	619-623	some	_
4-31	624-632	reported	_
4-32	633-640	greater	_
4-33	641-653	deactivation	_
4-34	654-655	.	_

5-1	656-658	An	_
5-2	659-668	inability	_
5-3	669-671	to	_
5-4	672-676	stay	_
5-5	677-684	engaged	_
5-6	685-687	in	_
5-7	688-691	the	_
5-8	692-701	cognitive	_
5-9	702-712	operations	_
5-10	713-718	could	_
5-11	719-726	account	_
5-12	727-730	for	_
5-13	731-736	these	_
5-14	737-750	discrepancies	_
5-15	751-752	,	_
5-16	753-756	too	_
5-17	757-758	,	_
5-18	759-761	as	_
5-19	762-764	it	_
5-20	765-770	would	_
5-21	771-775	lead	_
5-22	776-778	to	_
5-23	779-783	more	_
5-24	784-788	time	_
5-25	789-797	off-task	_
5-26	798-801	and	_
5-27	802-814	consequently	_
5-28	815-819	less	_
5-29	820-832	deactivation	_
5-30	833-835	of	_
5-31	836-839	DMN	_
5-32	840-849	functions	_
5-33	850-851	.	_

6-1	852-855	The	_
6-2	856-863	present	_
6-3	864-869	study	_
6-4	870-878	employed	_
6-5	879-880	a	_
6-6	881-887	change	_
6-7	888-897	detection	_
6-8	898-906	paradigm	_
6-9	907-911	with	_
6-10	912-917	small	_
6-11	918-920	to	_
6-12	921-929	moderate	_
6-13	930-933	set	_
6-14	934-939	sizes	_
6-15	940-941	(	_
6-16	942-945	SSs	_
6-17	946-947	)	_
6-18	948-950	of	_
6-19	951-952	1	_
6-20	953-954	,	_
6-21	955-956	2	_
6-22	957-958	,	_
6-23	959-962	and	_
6-24	963-964	4	_
6-25	965-970	items	_
6-26	971-972	.	_

7-1	973-977	Task	_
7-2	978-986	training	_
7-3	987-992	prior	_
7-4	993-995	to	_
7-5	996-1000	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
7-6	1001-1009	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
7-7	1010-1019	abolished	_
7-8	1020-1023	the	_
7-9	1024-1029	group	_
7-10	1030-1040	difference	_
7-11	1041-1043	in	_
7-12	1044-1055	no-response	_
7-13	1056-1062	trials	_
7-14	1063-1064	.	_

8-1	1065-1078	Task-positive	_
8-2	1079-1086	regions	_
8-3	1087-1089	of	_
8-4	1090-1098	interest	_
8-5	1099-1100	(	_
8-6	1101-1105	ROIs	_
8-7	1106-1107	)	_
8-8	1108-1117	displayed	_
8-9	1118-1125	greater	_
8-10	1126-1136	activation	_
8-11	1137-1141	with	_
8-12	1142-1152	increasing	_
8-13	1153-1155	SS	_
8-14	1156-1158	in	_
8-15	1159-1163	both	_
8-16	1164-1170	groups	_
8-17	1171-1172	.	_

9-1	1173-1176	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-2	1177-1183	showed	_
9-3	1184-1191	greater	_
9-4	1192-1202	activation	_
9-5	1203-1211	relative	_
9-6	1212-1214	to	_
9-7	1215-1218	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
9-8	1219-1221	at	_
9-9	1222-1225	SSs	_
9-10	1226-1227	1	_
9-11	1228-1231	and	_
9-12	1232-1233	2	_
9-13	1234-1235	.	_

10-1	1236-1239	DMN	_
10-2	1240-1244	ROIs	_
10-3	1245-1254	displayed	_
10-4	1255-1262	greater	_
10-5	1263-1275	deactivation	_
10-6	1276-1280	with	_
10-7	1281-1291	increasing	_
10-8	1292-1294	SS	_
10-9	1295-1297	in	_
10-10	1298-1301	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-11	1302-1303	,	_
10-12	1304-1307	but	_
10-13	1308-1311	not	_
10-14	1312-1314	in	_
10-15	1315-1318	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-16	1319-1320	,	_
10-17	1321-1324	and	_
10-18	1325-1328	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
10-19	1329-1335	tended	_
10-20	1336-1338	to	_
10-21	1339-1354	hyperdeactivate	_
10-22	1355-1358	DMN	_
10-23	1359-1366	regions	_
10-24	1367-1369	at	_
10-25	1370-1372	SS	_
10-26	1373-1374	4	_
10-27	1375-1376	.	_

11-1	1377-1379	No	_
11-2	1380-1396	hypodeactivation	_
11-3	1397-1400	was	_
11-4	1401-1409	observed	_
11-5	1410-1412	in	_
11-6	1413-1416	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
11-7	1417-1418	.	_

12-1	1419-1421	In	_
12-2	1422-1432	conclusion	_
12-3	1433-1434	,	_
12-4	1435-1439	when	_
12-5	1440-1450	minimizing	_
12-6	1451-1462	differences	_
12-7	1463-1465	in	_
12-8	1466-1481	task-engagement	_
12-9	1482-1483	,	_
12-10	1484-1487	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
12-11	1488-1492	tend	_
12-12	1493-1495	to	_
12-13	1496-1508	over-recruit	_
12-14	1509-1522	task-positive	_
12-15	1523-1530	regions	_
12-16	1531-1537	during	_
12-17	1538-1546	low-load	_
12-18	1547-1557	operations	_
12-19	1558-1559	,	_
12-20	1560-1563	and	_
12-21	1564-1579	hyperdeactivate	_
12-22	1580-1583	DMN	_
12-23	1584-1593	functions	_
12-24	1594-1596	at	_
12-25	1597-1603	higher	_
12-26	1604-1608	load	_
12-27	1609-1610	,	_
12-28	1611-1618	perhaps	_
12-29	1619-1629	reflecting	_
12-30	1630-1640	heightened	_
12-31	1641-1653	non-specific	_
12-32	1654-1663	vigilance	_
12-33	1664-1666	or	_
12-34	1667-1673	effort	_
12-35	1674-1678	when	_
12-36	1679-1686	dealing	_
12-37	1687-1691	with	_
12-38	1692-1701	cognitive	_
12-39	1702-1712	challenges	_
12-40	1713-1714	.	_

13-1	1715-1719	This	_
13-2	1720-1726	speaks	_
13-3	1727-1734	against	_
13-4	1735-1737	an	_
13-5	1738-1747	inability	_
13-6	1748-1750	to	_
13-7	1751-1764	down-regulate	_
13-8	1765-1781	task-independent	_
13-9	1782-1789	thought	_
13-10	1790-1799	processes	_
13-11	1800-1802	as	_
13-12	1803-1804	a	_
13-13	1805-1812	primary	_
13-14	1813-1822	mechanism	_
13-15	1823-1833	underlying	_
13-16	1834-1843	cognitive	_
13-17	1844-1854	impairment	_
13-18	1855-1857	in	_
13-19	1858-1871	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-20	1872-1873	.	_

14-1	1874-1883	Materials	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-2	1884-1887	and	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-3	1888-1895	Methods	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
14-4	1896-1908	Participants	_
14-5	1909-1919	Twenty-two	_
14-6	1920-1929	medicated	_
14-7	1930-1931	(	_
14-8	1932-1938	detail	_
14-9	1939-1941	in	_
14-10	1942-1952	Supplement	_
14-11	1953-1954	)	_
14-12	1955-1966	outpatients	_
14-13	1967-1974	meeting	_
14-14	1975-1981	DSM-IV	_
14-15	1982-1990	criteria	_
14-16	1991-1994	for	_
14-17	1995-2008	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
14-18	2009-2010	(	_
14-19	2011-2015	N=21	_
14-20	2016-2017	)	_
14-21	2018-2020	or	_
14-22	2021-2036	schizoaffective	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
14-23	2037-2045	disorder	http://maven.renci.org/NeuroBridge/neurobridge#BipolarTypeSchizoaffectiveDisorder
14-24	2046-2047	(	_
14-25	2048-2051	N=1	_
14-26	2052-2053	)	_
14-27	2054-2055	,	_
14-28	2056-2059	and	_
14-29	2060-2062	20	_
14-30	2063-2066	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-31	2067-2068	,	_
14-32	2069-2072	all	_
14-33	2073-2085	right-handed	_
14-34	2086-2087	,	_
14-35	2088-2097	completed	_
14-36	2098-2102	this	_
14-37	2103-2108	study	_
14-38	2109-2110	.	_

15-1	2111-2115	Data	_
15-2	2116-2120	from	_
15-3	2121-2125	four	_
15-4	2126-2129	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-5	2130-2133	and	_
15-6	2134-2137	one	_
15-7	2138-2141	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
15-8	2142-2146	were	_
15-9	2147-2155	excluded	_
15-10	2156-2163	because	_
15-11	2164-2168	they	_
15-12	2169-2177	appeared	_
15-13	2178-2180	to	_
15-14	2181-2183	be	_
15-15	2184-2190	asleep	_
15-16	2191-2197	during	_
15-17	2198-2203	parts	_
15-18	2204-2206	of	_
15-19	2207-2210	the	_
15-20	2211-2215	scan	_
15-21	2216-2217	.	_

16-1	2218-2229	Demographic	_
16-2	2230-2241	information	_
16-3	2242-2244	of	_
16-4	2245-2248	the	_
16-5	2249-2258	remaining	_
16-6	2259-2271	participants	_
16-7	2272-2274	is	_
16-8	2275-2285	summarized	_
16-9	2286-2288	in	_
16-10	2289-2294	Table	_
16-11	2295-2296	1	_
16-12	2297-2298	.	_

17-1	2299-2305	Groups	_
17-2	2306-2309	did	_
17-3	2310-2313	not	_
17-4	2314-2320	differ	_
17-5	2321-2323	in	_
17-6	2324-2327	age	_
17-7	2328-2329	,	_
17-8	2330-2333	sex	_
17-9	2334-2335	,	_
17-10	2336-2345	ethnicity	_
17-11	2346-2347	,	_
17-12	2348-2350	or	_
17-13	2351-2359	parental	_
17-14	2360-2369	education	_
17-15	2370-2371	.	_

18-1	2372-2375	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
18-2	2376-2382	tended	_
18-3	2383-2385	to	_
18-4	2386-2390	have	_
18-5	2391-2396	fewer	_
18-6	2397-2402	years	_
18-7	2403-2405	of	_
18-8	2406-2415	education	_
18-9	2416-2417	(	_
18-10	2418-2419	P	_
18-11	2420-2421	<	_
18-12	2422-2425	0.1	_
18-13	2426-2427	)	_
18-14	2428-2431	and	_
18-15	2432-2438	scored	_
18-16	2439-2444	lower	_
18-17	2445-2447	on	_
18-18	2448-2466	neuropsychological	_
18-19	2467-2472	tests	_
18-20	2473-2475	of	_
18-21	2476-2485	cognition	_
18-22	2486-2487	.	_

19-1	2488-2495	Because	_
19-2	2496-2501	blood	_
19-3	2502-2510	pressure	_
19-4	2511-2514	can	_
19-5	2515-2521	affect	_
19-6	2522-2526	BOLD	_
19-7	2527-2536	responses	_
19-8	2537-2539	to	_
19-9	2540-2548	neuronal	_
19-10	2549-2559	activation	_
19-11	2560-2561	,	_
19-12	2562-2564	we	_
19-13	2565-2573	compared	_
19-14	2574-2580	groups	_
19-15	2581-2583	on	_
19-16	2584-2592	systolic	_
19-17	2593-2594	(	_
19-18	2595-2596	P	_
19-19	2597-2598	>	_
19-20	2599-2602	0.6	_
19-21	2603-2604	)	_
19-22	2605-2608	and	_
19-23	2609-2618	diastolic	_
19-24	2619-2624	blood	_
19-25	2625-2633	pressure	_
19-26	2634-2635	(	_
19-27	2636-2637	P	_
19-28	2638-2639	>	_
19-29	2640-2643	0.3	_
19-30	2644-2645	)	_
19-31	2646-2647	.	_

20-1	2648-2660	Participants	_
20-2	2661-2669	provided	_
20-3	2670-2678	informed	_
20-4	2679-2686	consent	_
20-5	2687-2690	for	_
20-6	2691-2692	a	_
20-7	2693-2701	protocol	_
20-8	2702-2710	approved	_
20-9	2711-2713	by	_
20-10	2714-2717	the	_
20-11	2718-2731	Institutional	_
20-12	2732-2738	Review	_
20-13	2739-2745	Boards	_
20-14	2746-2748	of	_
20-15	2749-2752	the	_
20-16	2753-2763	University	_
20-17	2764-2766	of	_
20-18	2767-2775	Maryland	_
20-19	2776-2777	,	_
20-20	2778-2787	Baltimore	_
20-21	2788-2789	,	_
20-22	2790-2793	and	_
20-23	2794-2797	the	_
20-24	2798-2806	National	_
20-25	2807-2816	Institute	_
20-26	2817-2819	on	_
20-27	2820-2824	Drug	_
20-28	2825-2830	Abuse	_
20-29	2831-2832	–	_
20-30	2833-2843	Intramural	_
20-31	2844-2852	Research	_
20-32	2853-2860	Program	_
20-33	2861-2862	.	_

21-1	2863-2872	Procedure	_
21-2	2873-2879	During	_
21-3	2880-2882	an	_
21-4	2883-2890	initial	_
21-5	2891-2899	training	_
21-6	2900-2907	session	_
21-7	2908-2909	,	_
21-8	2910-2922	participants	_
21-9	2923-2931	received	_
21-10	2932-2936	task	_
21-11	2937-2949	instructions	_
21-12	2950-2951	,	_
21-13	2952-2961	performed	_
21-14	2962-2965	the	_
21-15	2966-2977	full-length	_
21-16	2978-2983	tasks	_
21-17	2984-2986	on	_
21-18	2987-2988	a	_
21-19	2989-2991	PC	_
21-20	2992-2993	,	_
21-21	2994-2997	and	_
21-22	2998-3007	completed	_
21-23	3008-3026	neuropsychological	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
21-24	3027-3034	testing	http://maven.renci.org/NeuroBridge/neurobridge#CambridgeNeuropsychologicalTestAutomatedBattery
21-25	3035-3036	.	_

22-1	3037-3045	Training	_
22-2	3046-3057	performance	_
22-3	3058-3062	data	_
22-4	3063-3067	from	_
22-5	3068-3071	one	_
22-6	3072-3075	PSZ	_
22-7	3076-3079	was	_
22-8	3080-3084	lost	_
22-9	3085-3088	due	_
22-10	3089-3091	to	_
22-11	3092-3101	recording	_
22-12	3102-3108	errors	_
22-13	3109-3110	.	_

23-1	3111-3116	Scans	_
23-2	3117-3121	were	_
23-3	3122-3128	always	_
23-4	3129-3138	performed	_
23-5	3139-3141	on	_
23-6	3142-3143	a	_
23-7	3144-3152	separate	_
23-8	3153-3156	day	_
23-9	3157-3159	to	_
23-10	3160-3165	avoid	_
23-11	3166-3176	exhaustion	_
23-12	3177-3178	.	_

24-1	3179-3191	Participants	_
24-2	3192-3201	performed	_
24-3	3202-3205	two	_
24-4	3206-3211	tasks	_
24-5	3212-3217	while	_
24-6	3218-3228	undergoing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
24-7	3229-3233	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
24-8	3234-3235	:	_
24-9	3236-3241	first	_
24-10	3242-3243	a	_
24-11	3244-3252	stimulus	_
24-12	3253-3262	detection	_
24-13	3263-3267	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
24-14	3268-3269	,	_
24-15	3270-3278	reported	_
24-16	3279-3288	elsewhere	_
24-17	3289-3290	,	_
24-18	3291-3295	then	_
24-19	3296-3299	the	_
24-20	3300-3303	CDT	_
24-21	3304-3313	described	_
24-22	3314-3319	below	_
24-23	3320-3321	.	_

25-1	3322-3324	An	_
25-2	3325-3335	anatomical	_
25-3	3336-3340	scan	_
25-4	3341-3344	was	_
25-5	3345-3353	obtained	_
25-6	3354-3361	between	_
25-7	3362-3367	tasks	_
25-8	3368-3369	.	_

26-1	3370-3373	The	_
26-2	3374-3377	CDT	_
26-3	3378-3381	was	_
26-4	3382-3390	preceded	_
26-5	3391-3393	by	_
26-6	3394-3398	four	_
26-7	3399-3405	blocks	_
26-8	3406-3408	of	_
26-9	3409-3410	a	_
26-10	3411-3421	visuomotor	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
26-11	3422-3429	control	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
26-12	3430-3434	task	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
26-13	3435-3436	,	_
26-14	3437-3440	not	_
26-15	3441-3449	reported	_
26-16	3450-3454	here	_
26-17	3455-3456	.	_

27-1	3457-3460	The	_
27-2	3461-3464	CDT	_
27-3	3465-3468	The	_
27-4	3469-3475	design	_
27-5	3476-3479	was	_
27-6	3480-3485	first	_
27-7	3486-3495	described	_
27-8	3496-3498	by	_
27-9	3499-3500	.	_

28-1	3501-3513	Participants	_
28-2	3514-3520	viewed	_
28-3	3521-3522	a	_
28-4	3523-3529	200-ms	_
28-5	3530-3538	encoding	_
28-6	3539-3544	array	_
28-7	3545-3547	of	_
28-8	3548-3549	1	_
28-9	3550-3551	,	_
28-10	3552-3553	2	_
28-11	3554-3555	,	_
28-12	3556-3558	or	_
28-13	3559-3560	4	_
28-14	3561-3568	colored	_
28-15	3569-3576	squares	_
28-16	3577-3578	,	_
28-17	3579-3586	circles	_
28-18	3587-3588	,	_
28-19	3589-3591	or	_
28-20	3592-3601	triangles	_
28-21	3602-3603	(	_
28-22	3604-3608	each	_
28-23	3609-3620	participant	_
28-24	3621-3624	was	_
28-25	3625-3634	allocated	_
28-26	3635-3638	one	_
28-27	3639-3644	shape	_
28-28	3645-3646	)	_
28-29	3647-3654	against	_
28-30	3655-3656	a	_
28-31	3657-3662	black	_
28-32	3663-3673	background	_
28-33	3674-3675	(	_
28-34	3676-3682	Figure	_
28-35	3683-3685	1A	_
28-36	3686-3687	)	_
28-37	3688-3689	.	_

29-1	3690-3695	After	_
29-2	3696-3697	a	_
29-3	3698-3705	1100-ms	_
29-4	3706-3718	blank-screen	_
29-5	3719-3724	delay	_
29-6	3725-3726	,	_
29-7	3727-3730	one	_
29-8	3731-3733	of	_
29-9	3734-3737	the	_
29-10	3738-3743	shape	_
29-11	3744-3751	stimuli	_
29-12	3752-3762	reappeared	_
29-13	3763-3766	for	_
29-14	3767-3771	2000	_
29-15	3772-3774	ms	_
29-16	3775-3776	.	_

30-1	3777-3780	The	_
30-2	3781-3785	task	_
30-3	3786-3789	was	_
30-4	3790-3792	to	_
30-5	3793-3797	make	_
30-6	3798-3800	an	_
30-7	3801-3806	index	_
30-8	3807-3813	finger	_
30-9	3814-3822	response	_
30-10	3823-3825	if	_
30-11	3826-3829	the	_
30-12	3830-3835	shape	_
30-13	3836-3840	that	_
30-14	3841-3844	had	_
30-15	3845-3849	been	_
30-16	3850-3859	presented	_
30-17	3860-3862	at	_
30-18	3863-3867	this	_
30-19	3868-3876	location	_
30-20	3877-3884	changed	_
30-21	3885-3890	color	_
30-22	3891-3892	,	_
30-23	3893-3896	and	_
30-24	3897-3898	a	_
30-25	3899-3905	middle	_
30-26	3906-3912	finger	_
30-27	3913-3921	response	_
30-28	3922-3924	if	_
30-29	3925-3928	the	_
30-30	3929-3934	color	_
30-31	3935-3941	stayed	_
30-32	3942-3945	the	_
30-33	3946-3950	same	_
30-34	3951-3952	(	_
30-35	3953-3955	50	_
30-36	3956-3957	%	_
30-37	3958-3969	probability	_
30-38	3970-3971	)	_
30-39	3972-3973	.	_

31-1	3974-3980	Trials	_
31-2	3981-3985	were	_
31-3	3986-3995	separated	_
31-4	3996-3998	by	_
31-5	3999-4000	a	_
31-6	4001-4008	1000-ms	_
31-7	4009-4019	intertrial	_
31-8	4020-4028	interval	_
31-9	4029-4030	.	_

32-1	4031-4034	The	_
32-2	4035-4041	larger	_
32-3	4042-4043	a	_
32-4	4044-4055	participant	_
32-5	4056-4057	’	_
32-6	4058-4059	s	_
32-7	4060-4062	WM	_
32-8	4063-4071	capacity	_
32-9	4072-4073	,	_
32-10	4074-4077	the	_
32-11	4078-4082	more	_
32-12	4083-4088	items	_
32-13	4089-4092	are	_
32-14	4093-4100	encoded	_
32-15	4101-4102	,	_
32-16	4103-4106	and	_
32-17	4107-4110	the	_
32-18	4111-4118	greater	_
32-19	4119-4122	the	_
32-20	4123-4134	probability	_
32-21	4135-4137	of	_
32-22	4138-4139	a	_
32-23	4140-4147	correct	_
32-24	4148-4156	response	_
32-25	4157-4158	.	_

33-1	4159-4164	While	_
33-2	4165-4172	ceiling	_
33-3	4173-4180	effects	_
33-4	4181-4184	are	_
33-5	4185-4191	likely	_
33-6	4192-4194	at	_
33-7	4195-4197	SS	_
33-8	4198-4199	1	_
33-9	4200-4203	and	_
33-10	4204-4205	2	_
33-11	4206-4207	,	_
33-12	4208-4210	SS	_
33-13	4211-4212	4	_
33-14	4213-4221	somewhat	_
33-15	4222-4229	exceeds	_
33-16	4230-4233	the	_
33-17	4234-4242	capacity	_
33-18	4243-4245	of	_
33-19	4246-4250	most	_
33-20	4251-4263	participants	_
33-21	4264-4267	and	_
33-22	4268-4272	thus	_
33-23	4273-4275	is	_
33-24	4276-4285	sensitive	_
33-25	4286-4288	to	_
33-26	4289-4294	group	_
33-27	4295-4306	differences	_
33-28	4307-4309	in	_
33-29	4310-4312	WM	_
33-30	4313-4321	capacity	_
33-31	4322-4323	.	_

34-1	4324-4333	Dependent	_
34-2	4334-4343	variables	_
34-3	4344-4348	were	_
34-4	4349-4357	accuracy	_
34-5	4358-4359	,	_
34-6	4360-4370	reflecting	_
34-7	4371-4374	the	_
34-8	4375-4385	percentage	_
34-9	4386-4388	of	_
34-10	4389-4396	correct	_
34-11	4397-4404	choices	_
34-12	4405-4406	(	_
34-13	4407-4413	chance	_
34-14	4414-4419	being	_
34-15	4420-4422	50	_
34-16	4423-4424	%	_
34-17	4425-4426	)	_
34-18	4427-4428	,	_
34-19	4429-4436	average	_
34-20	4437-4445	reaction	_
34-21	4446-4450	time	_
34-22	4451-4455	over	_
34-23	4456-4459	all	_
34-24	4460-4469	responses	_
34-25	4470-4471	,	_
34-26	4472-4475	and	_
34-27	4476-4487	no-response	_
34-28	4488-4494	trials	_
34-29	4495-4496	,	_
34-30	4497-4507	reflecting	_
34-31	4508-4511	the	_
34-32	4512-4522	percentage	_
34-33	4523-4525	of	_
34-34	4526-4532	trials	_
34-35	4533-4535	in	_
34-36	4536-4541	which	_
34-37	4542-4554	participants	_
34-38	4555-4561	failed	_
34-39	4562-4564	to	_
34-40	4565-4572	respond	_
34-41	4573-4574	.	_

35-1	4575-4578	The	_
35-2	4579-4583	task	_
35-3	4584-4587	was	_
35-4	4588-4597	presented	_
35-5	4598-4600	in	_
35-6	4601-4605	26-s	_
35-7	4606-4612	blocks	_
35-8	4613-4615	of	_
35-9	4616-4617	6	_
35-10	4618-4624	trials	_
35-11	4625-4629	each	_
35-12	4630-4631	(	_
35-13	4632-4633	3	_
35-14	4634-4640	change	_
35-15	4641-4642	,	_
35-16	4643-4644	3	_
35-17	4645-4654	no-change	_
35-18	4655-4656	)	_
35-19	4657-4658	.	_

36-1	4659-4662	All	_
36-2	4663-4669	trials	_
36-3	4670-4676	within	_
36-4	4677-4678	a	_
36-5	4679-4684	block	_
36-6	4685-4689	were	_
36-7	4690-4692	of	_
36-8	4693-4696	the	_
36-9	4697-4701	same	_
36-10	4702-4704	SS	_
36-11	4705-4706	(	_
36-12	4707-4712	block	_
36-13	4713-4719	design	_
36-14	4720-4728	analysis	_
36-15	4729-4730	)	_
36-16	4731-4732	.	_

37-1	4733-4738	Eight	_
37-2	4739-4743	scan	_
37-3	4744-4748	runs	_
37-4	4749-4750	(	_
37-5	4751-4755	each	_
37-6	4756-4759	178	_
37-7	4760-4761	s	_
37-8	4762-4763	,	_
37-9	4764-4766	or	_
37-10	4767-4769	89	_
37-11	4770-4773	TRs	_
37-12	4774-4775	)	_
37-13	4776-4780	were	_
37-14	4781-4790	separated	_
37-15	4791-4793	by	_
37-16	4794-4798	rest	_
37-17	4799-4806	periods	_
37-18	4807-4813	during	_
37-19	4814-4819	which	_
37-20	4820-4823	the	_
37-21	4824-4831	scanner	_
37-22	4832-4835	was	_
37-23	4836-4842	turned	_
37-24	4843-4846	off	_
37-25	4847-4848	.	_

38-1	4849-4853	Each	_
38-2	4854-4857	run	_
38-3	4858-4867	contained	_
38-4	4868-4871	one	_
38-5	4872-4877	block	_
38-6	4878-4880	of	_
38-7	4881-4885	each	_
38-8	4886-4888	SS	_
38-9	4889-4890	,	_
38-10	4891-4894	one	_
38-11	4895-4899	26-s	_
38-12	4900-4904	rest	_
38-13	4905-4910	block	_
38-14	4911-4917	during	_
38-15	4918-4923	which	_
38-16	4924-4936	participants	_
38-17	4937-4944	fixated	_
38-18	4945-4946	a	_
38-19	4947-4954	central	_
38-20	4955-4960	cross	_
38-21	4961-4962	,	_
38-22	4963-4966	and	_
38-23	4967-4970	two	_
38-24	4971-4977	blocks	_
38-25	4978-4980	in	_
38-26	4981-4986	which	_
38-27	4987-4993	either	_
38-28	4994-4997	one	_
38-29	4998-5006	relevant	_
38-30	5007-5010	and	_
38-31	5011-5014	one	_
38-32	5015-5025	irrelevant	_
38-33	5026-5027	,	_
38-34	5028-5030	or	_
38-35	5031-5034	two	_
38-36	5035-5043	relevant	_
38-37	5044-5047	and	_
38-38	5048-5051	two	_
38-39	5052-5062	irrelevant	_
38-40	5063-5069	shapes	_
38-41	5070-5074	were	_
38-42	5075-5084	presented	_
38-43	5085-5086	.	_

39-1	5087-5092	These	_
39-2	5093-5096	two	_
39-3	5097-5107	conditions	_
39-4	5108-5114	tapped	_
39-5	5115-5123	specific	_
39-6	5124-5134	hypotheses	_
39-7	5135-5140	about	_
39-8	5141-5151	mechanisms	_
39-9	5152-5154	of	_
39-10	5155-5164	selective	_
39-11	5165-5174	attention	_
39-12	5175-5177	in	_
39-13	5178-5181	PSZ	_
39-14	5182-5185	and	_
39-15	5186-5190	were	_
39-16	5191-5198	modeled	_
39-17	5199-5202	but	_
39-18	5203-5206	not	_
39-19	5207-5214	further	_
39-20	5215-5223	analyzed	_
39-21	5224-5227	for	_
39-22	5228-5231	the	_
39-23	5232-5240	purposes	_
39-24	5241-5243	of	_
39-25	5244-5248	this	_
39-26	5249-5254	study	_
39-27	5255-5256	.	_

40-1	5257-5265	Magnetic	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-2	5266-5275	resonance	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-3	5276-5283	imaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
40-4	5284-5285	A	_
40-5	5286-5287	3	_
40-6	5288-5293	Tesla	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
40-7	5294-5301	Siemens	_
40-8	5302-5305	Tim	_
40-9	5306-5310	Trio	_
40-10	5311-5318	scanner	_
40-11	5319-5320	(	_
40-12	5321-5329	Erlangen	_
40-13	5330-5331	,	_
40-14	5332-5339	Germany	_
40-15	5340-5341	)	_
40-16	5342-5350	acquired	_
40-17	5351-5362	whole-brain	_
40-18	5363-5366	EPI	_
40-19	5367-5373	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
40-20	5374-5377	for	_
40-21	5378-5387	measuring	_
40-22	5388-5390	T2	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-23	5391-5392	*	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-24	5393-5402	-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
40-25	5403-5407	BOLD	_
40-26	5408-5415	effects	_
40-27	5416-5417	[	_
40-28	5418-5422	4-mm	_
40-29	5423-5430	oblique	_
40-30	5431-5432	(	_
40-31	5433-5436	30º	_
40-32	5437-5438	)	_
40-33	5439-5444	axial	_
40-34	5445-5451	slices	_
40-35	5452-5453	,	_
40-36	5454-5459	64×64	_
40-37	5460-5466	matrix	_
40-38	5467-5468	,	_
40-39	5469-5478	FOV=22×22	_
40-40	5479-5481	cm	_
40-41	5482-5483	,	_
40-42	5484-5488	TR=2	_
40-43	5489-5490	s	_
40-44	5491-5492	,	_
40-45	5493-5498	TE=27	_
40-46	5499-5501	ms	_
40-47	5502-5503	]	_
40-48	5504-5505	.	_

41-1	5506-5508	An	_
41-2	5509-5514	axial	_
41-3	5515-5526	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-4	5527-5532	image	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-5	5533-5534	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-6	5535-5541	MPRAGE	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-7	5542-5543	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
41-8	5544-5552	provided	_
41-9	5553-5563	anatomical	_
41-10	5564-5573	reference	_
41-11	5574-5575	(	_
41-12	5576-5581	1-mm3	_
41-13	5582-5588	voxels	_
41-14	5589-5590	,	_
41-15	5591-5597	TR=1.9	_
41-16	5598-5599	s	_
41-17	5600-5601	,	_
41-18	5602-5609	TE=3.51	_
41-19	5610-5612	ms	_
41-20	5613-5614	,	_
41-21	5615-5620	FA=9º	_
41-22	5621-5622	)	_
41-23	5623-5624	.	_

42-1	5625-5629	Data	_
42-2	5630-5634	were	_
42-3	5635-5644	processed	_
42-4	5645-5650	using	_
42-5	5651-5655	AFNI	_
42-6	5656-5657	.	_

43-1	5658-5662	Each	_
43-2	5663-5669	volume	_
43-3	5670-5673	was	_
43-4	5674-5684	registered	_
43-5	5685-5687	to	_
43-6	5688-5689	a	_
43-7	5690-5694	base	_
43-8	5695-5701	volume	_
43-9	5702-5703	.	_

44-1	5704-5707	For	_
44-2	5708-5712	each	_
44-3	5713-5720	subject	_
44-4	5721-5722	,	_
44-5	5723-5724	a	_
44-6	5725-5734	composite	_
44-7	5735-5741	motion	_
44-8	5742-5747	index	_
44-9	5748-5751	was	_
44-10	5752-5762	calculated	_
44-11	5763-5767	from	_
44-12	5768-5771	the	_
44-13	5772-5775	six	_
44-14	5776-5782	motion	_
44-15	5783-5793	correction	_
44-16	5794-5804	parameters	_
44-17	5805-5806	(	_
44-18	5807-5811	Yang	_
44-19	5812-5814	et	_
44-20	5815-5818	al.	_
44-21	5819-5820	,	_
44-22	5821-5825	2005	_
44-23	5826-5827	)	_
44-24	5828-5829	.	_

45-1	5830-5835	These	_
45-2	5836-5842	scores	_
45-3	5843-5846	did	_
45-4	5847-5850	not	_
45-5	5851-5857	differ	_
45-6	5858-5865	between	_
45-7	5866-5869	HCS	http://maven.renci.org/NeuroBridge/neurobridge#Thing
45-8	5870-5873	and	_
45-9	5874-5877	PSZ	http://maven.renci.org/NeuroBridge/neurobridge#Thing
45-10	5878-5879	[	_
45-11	5880-5881	t	_
45-12	5882-5883	(	_
45-13	5884-5886	32	_
45-14	5887-5888	)	_
45-15	5889-5894	=1.66	_
45-16	5895-5896	,	_
45-17	5897-5898	P	_
45-18	5899-5900	>	_
45-19	5901-5904	0.1	_
45-20	5905-5906	]	_
45-21	5907-5908	.	_

46-1	5909-5912	TRs	_
46-2	5913-5917	with	_
46-3	5918-5919	>	_
46-4	5920-5923	0.5	_
46-5	5924-5926	mm	_
46-6	5927-5939	displacement	_
46-7	5940-5942	or	_
46-8	5943-5944	>	_
46-9	5945-5949	0.5°	_
46-10	5950-5958	rotation	_
46-11	5959-5967	relative	_
46-12	5968-5970	to	_
46-13	5971-5974	the	_
46-14	5975-5984	preceding	_
46-15	5985-5987	TR	_
46-16	5988-5992	were	_
46-17	5993-6001	censored	_
46-18	6002-6005	out	_
46-19	6006-6008	of	_
46-20	6009-6012	the	_
46-21	6013-6017	time	_
46-22	6018-6024	series	_
46-23	6025-6026	.	_

47-1	6027-6030	The	_
47-2	6031-6037	number	_
47-3	6038-6040	of	_
47-4	6041-6049	censored	_
47-5	6050-6053	TRs	_
47-6	6054-6057	did	_
47-7	6058-6061	not	_
47-8	6062-6068	differ	_
47-9	6069-6076	between	_
47-10	6077-6083	groups	_
47-11	6084-6085	[	_
47-12	6086-6087	t	_
47-13	6088-6089	(	_
47-14	6090-6092	35	_
47-15	6093-6094	)	_
47-16	6095-6100	=0.60	_
47-17	6101-6102	,	_
47-18	6103-6104	P	_
47-19	6105-6106	>	_
47-20	6107-6110	0.5	_
47-21	6111-6112	]	_
47-22	6113-6114	.	_

48-1	6115-6118	The	_
48-2	6119-6123	time	_
48-3	6124-6130	series	_
48-4	6131-6134	was	_
48-5	6135-6143	analyzed	_
48-6	6144-6146	by	_
48-7	6147-6157	voxel-wise	_
48-8	6158-6166	multiple	_
48-9	6167-6177	regression	_
48-10	6178-6179	.	_

49-1	6180-6184	Five	_
49-2	6185-6189	26-s	_
49-3	6190-6196	boxcar	_
49-4	6197-6207	regressors	_
49-5	6208-6209	,	_
49-6	6210-6223	corresponding	_
49-7	6224-6226	to	_
49-8	6227-6233	blocks	_
49-9	6234-6238	with	_
49-10	6239-6240	1	_
49-11	6241-6242	,	_
49-12	6243-6244	2	_
49-13	6245-6246	,	_
49-14	6247-6250	and	_
49-15	6251-6252	4	_
49-16	6253-6257	item	_
49-17	6258-6264	trials	_
49-18	6265-6266	,	_
49-19	6267-6270	and	_
49-20	6271-6273	to	_
49-21	6274-6277	the	_
49-22	6278-6281	two	_
49-23	6282-6288	blocks	_
49-24	6289-6298	involving	_
49-25	6299-6310	distractors	_
49-26	6311-6312	(	_
49-27	6313-6316	see	_
49-28	6317-6320	2.3	_
49-29	6321-6322	)	_
49-30	6323-6324	,	_
49-31	6325-6329	were	_
49-32	6330-6339	convolved	_
49-33	6340-6344	with	_
49-34	6345-6346	a	_
49-35	6347-6352	model	_
49-36	6353-6364	hemodynamic	_
49-37	6365-6373	response	_
49-38	6374-6382	function	_
49-39	6383-6384	.	_

50-1	6385-6388	The	_
50-2	6389-6392	six	_
50-3	6393-6399	motion	_
50-4	6400-6409	parameter	_
50-5	6410-6416	curves	_
50-6	6417-6421	were	_
50-7	6422-6430	included	_
50-8	6431-6433	as	_
50-9	6434-6444	regressors	_
50-10	6445-6447	of	_
50-11	6448-6450	no	_
50-12	6451-6459	interest	_
50-13	6460-6461	.	_

51-1	6462-6465	All	_
51-2	6466-6478	correlations	_
51-3	6479-6486	between	_
51-4	6487-6490	any	_
51-5	6491-6493	of	_
51-6	6494-6499	three	_
51-7	6500-6510	regressors	_
51-8	6511-6513	of	_
51-9	6514-6522	interest	_
51-10	6523-6526	and	_
51-11	6527-6530	any	_
51-12	6531-6533	of	_
51-13	6534-6537	the	_
51-14	6538-6544	motion	_
51-15	6545-6555	regressors	_
51-16	6556-6560	were	_
51-17	6561-6565	near	_
51-18	6566-6570	zero	_
51-19	6571-6572	(	_
51-20	6573-6576	all	_
51-21	6577-6579	Ps	_
51-22	6580-6581	>	_
51-23	6582-6585	0.9	_
51-24	6586-6587	)	_
51-25	6588-6589	,	_
51-26	6590-6593	and	_
51-27	6594-6597	the	_
51-28	6598-6604	groups	_
51-29	6605-6608	did	_
51-30	6609-6612	not	_
51-31	6613-6619	differ	_
51-32	6620-6622	in	_
51-33	6623-6630	average	_
51-34	6631-6650	stimulus-correlated	_
51-35	6651-6657	motion	_
51-36	6658-6659	[	_
51-37	6660-6661	t	_
51-38	6662-6663	(	_
51-39	6664-6666	35	_
51-40	6667-6668	)	_
51-41	6669-6674	=0.50	_
51-42	6675-6676	,	_
51-43	6677-6678	P	_
51-44	6679-6680	>	_
51-45	6681-6684	0.6	_
51-46	6685-6686	]	_
51-47	6687-6688	.	_

52-1	6689-6692	For	_
52-2	6693-6697	each	_
52-3	6698-6705	subject	_
52-4	6706-6707	,	_
52-5	6708-6711	the	_
52-6	6712-6722	voxel-wise	_
52-7	6723-6730	average	_
52-8	6731-6740	amplitude	_
52-9	6741-6743	of	_
52-10	6744-6750	signal	_
52-11	6751-6757	change	_
52-12	6758-6766	produced	_
52-13	6767-6769	by	_
52-14	6770-6774	each	_
52-15	6775-6777	of	_
52-16	6778-6781	the	_
52-17	6782-6787	three	_
52-18	6788-6791	SSs	_
52-19	6792-6800	relative	_
52-20	6801-6803	to	_
52-21	6804-6808	rest	_
52-22	6809-6815	blocks	_
52-23	6816-6819	was	_
52-24	6820-6830	determined	_
52-25	6831-6832	.	_

53-1	6833-6838	These	_
53-2	6839-6843	maps	_
53-3	6844-6848	were	_
53-4	6849-6859	re-sampled	_
53-5	6860-6862	to	_
53-6	6863-6864	a	_
53-7	6865-6869	1-μL	_
53-8	6870-6880	resolution	_
53-9	6881-6882	,	_
53-10	6883-6892	converted	_
53-11	6893-6895	to	_
53-12	6896-6897	a	_
53-13	6898-6906	standard	_
53-14	6907-6917	coordinate	_
53-15	6918-6924	system	_
53-16	6925-6926	,	_
53-17	6927-6930	and	_
53-18	6931-6940	spatially	_
53-19	6941-6948	blurred	_
53-20	6949-6950	.	_

54-1	6951-6963	Second-level	_
54-2	6964-6972	analyses	_
54-3	6973-6974	:	_
54-4	6975-6978	For	_
54-5	6979-6992	visualization	_
54-6	6993-6995	of	_
54-7	6996-7008	SS-dependent	_
54-8	7009-7017	activity	_
54-9	7018-7024	within	_
54-10	7025-7028	PSZ	_
54-11	7029-7032	and	_
54-12	7033-7039	within	_
54-13	7040-7043	HCS	_
54-14	7044-7045	,	_
54-15	7046-7047	a	_
54-16	7048-7056	Gaussian	_
54-17	7057-7061	5-mm	_
54-18	7062-7066	root	_
54-19	7067-7071	mean	_
54-20	7072-7078	square	_
54-21	7079-7080	(	_
54-22	7081-7084	RMS	_
54-23	7085-7086	)	_
54-24	7087-7096	isotropic	_
54-25	7097-7103	kernel	_
54-26	7104-7107	was	_
54-27	7108-7115	adopted	_
54-28	7116-7117	.	_

55-1	7118-7129	Whole-brain	_
55-2	7130-7140	voxel-wise	_
55-3	7141-7149	multiple	_
55-4	7150-7156	linear	_
55-5	7157-7167	regression	_
55-6	7168-7171	was	_
55-7	7172-7181	performed	_
55-8	7182-7188	within	_
55-9	7189-7193	each	_
55-10	7194-7202	separate	_
55-11	7203-7208	group	_
55-12	7209-7210	,	_
55-13	7211-7215	with	_
55-14	7216-7218	SS	_
55-15	7219-7221	as	_
55-16	7222-7225	the	_
55-17	7226-7235	regressor	_
55-18	7236-7238	of	_
55-19	7239-7247	interest	_
55-20	7248-7249	.	_

56-1	7250-7260	Voxel-wise	_
56-2	7261-7262	P	_
56-3	7263-7264	<	_
56-4	7265-7270	0.001	_
56-5	7271-7279	combined	_
56-6	7280-7284	with	_
56-7	7285-7286	a	_
56-8	7287-7293	438-μL	_
56-9	7294-7305	clustersize	_
56-10	7306-7315	threshold	_
56-11	7316-7323	yielded	_
56-12	7324-7331	overall	_
56-13	7332-7333	P	_
56-14	7334-7335	<	_
56-15	7336-7340	0.05	_
56-16	7341-7346	based	_
56-17	7347-7349	on	_
56-18	7350-7355	Monte	_
56-19	7356-7361	Carlo	_
56-20	7362-7373	simulations	_
56-21	7374-7375	.	_

57-1	7376-7379	For	_
57-2	7380-7386	direct	_
57-3	7387-7398	statistical	_
57-4	7399-7405	groups	_
57-5	7406-7417	comparisons	_
57-6	7418-7423	based	_
57-7	7424-7426	on	_
57-8	7427-7438	pre-defined	_
57-9	7439-7446	regions	_
57-10	7447-7449	of	_
57-11	7450-7458	interest	_
57-12	7459-7460	(	_
57-13	7461-7465	ROIs	_
57-14	7466-7467	)	_
57-15	7468-7469	,	_
57-16	7470-7471	a	_
57-17	7472-7477	10-mm	_
57-18	7478-7481	RMS	_
57-19	7482-7488	kernel	_
57-20	7489-7492	was	_
57-21	7493-7500	applied	_
57-22	7501-7503	to	_
57-23	7504-7512	minimize	_
57-24	7513-7516	the	_
57-25	7517-7523	impact	_
57-26	7524-7526	of	_
57-27	7527-7540	morphological	_
57-28	7541-7552	differences	_
57-29	7553-7560	between	_
57-30	7561-7564	PSZ	_
57-31	7565-7568	and	_
57-32	7569-7572	HCS	_
57-33	7573-7574	(	_
57-34	7575-7579	e.g.	_
57-35	7580-7581	,	_
57-36	7582-7583	)	_
57-37	7584-7587	and	_
57-38	7588-7594	reduce	_
57-39	7595-7598	the	_
57-40	7599-7603	risk	_
57-41	7604-7606	of	_
57-42	7607-7612	group	_
57-43	7613-7624	differences	_
57-44	7625-7627	in	_
57-45	7628-7636	regional	_
57-46	7637-7647	activation	_
57-47	7648-7657	resulting	_
57-48	7658-7662	from	_
57-49	7663-7672	comparing	_
57-50	7673-7690	non-corresponding	_
57-51	7691-7701	anatomical	_
57-52	7702-7707	areas	_
57-53	7708-7709	.	_

58-1	7710-7714	ROIs	_
58-2	7715-7719	were	_
58-3	7720-7727	defined	_
58-4	7728-7730	by	_
58-5	7731-7733	an	_
58-6	7734-7745	independent	_
58-7	7746-7751	study	_
58-8	7752-7753	,	_
58-9	7754-7756	to	_
58-10	7757-7762	avoid	_
58-11	7763-7767	bias	_
58-12	7768-7775	through	_
58-13	7776-7777	“	_
58-14	7778-7784	double	_
58-15	7785-7792	dipping	_
58-16	7793-7794	”	_
58-17	7795-7796	.	_

59-1	7797-7814	Seven-mm-diameter	_
59-2	7815-7822	spheres	_
59-3	7823-7827	were	_
59-4	7828-7836	centered	_
59-5	7837-7839	on	_
59-6	7840-7844	peak	_
59-7	7845-7849	foci	_
59-8	7850-7852	of	_
59-9	7853-7856	the	_
59-10	7857-7870	task-positive	_
59-11	7871-7872	(	_
59-12	7873-7875	16	_
59-13	7876-7880	ROIs	_
59-14	7881-7882	)	_
59-15	7883-7886	and	_
59-16	7887-7890	DMN	_
59-17	7891-7892	(	_
59-18	7893-7895	13	_
59-19	7896-7900	ROIs	_
59-20	7901-7902	)	_
59-21	7903-7911	networks	_
59-22	7912-7922	identified	_
59-23	7923-7925	by	_
59-24	7926-7927	;	_
59-25	7928-7932	page	_
59-26	7933-7937	9676	_
59-27	7938-7939	)	_
59-28	7940-7945	based	_
59-29	7946-7948	on	_
59-30	7949-7960	spontaneous	_
59-31	7961-7973	correlations	_
59-32	7974-7977	and	_
59-33	7978-7994	anticorrelations	_
59-34	7995-7997	at	_
59-35	7998-8002	rest	_
59-36	8003-8004	.	_

60-1	8005-8009	Thus	_
60-2	8010-8011	,	_
60-3	8012-8015	ROI	_
60-4	8016-8026	definition	_
60-5	8027-8030	was	_
60-6	8031-8034	not	_
60-7	8035-8041	biased	_
60-8	8042-8044	by	_
60-9	8045-8053	specific	_
60-10	8054-8058	task	_
60-11	8059-8066	demands	_
60-12	8067-8068	.	_

61-1	8069-8077	Activity	_
61-2	8078-8081	was	_
61-3	8082-8090	averaged	_
61-4	8091-8097	within	_
61-5	8098-8102	each	_
61-6	8103-8106	ROI	_
61-7	8107-8108	.	_

62-1	8109-8122	Task-positive	_
62-2	8123-8126	and	_
62-3	8127-8130	DMN	_
62-4	8131-8135	ROIs	_
62-5	8136-8140	were	_
62-6	8141-8149	analyzed	_
62-7	8150-8152	by	_
62-8	8153-8156	two	_
62-9	8157-8165	separate	_
62-10	8166-8178	three-factor	_
62-11	8179-8185	ANOVAs	_
62-12	8186-8187	(	_
62-13	8188-8193	group	_
62-14	8194-8195	×	_
62-15	8196-8198	SS	_
62-16	8199-8200	×	_
62-17	8201-8204	ROI	_
62-18	8205-8206	)	_
62-19	8207-8208	.	_

